Benlysta (belimumab) is a biologic drug used to treat systemic lupus erythematosus (SLE), an autoimmune disorder. It is the first and only FDA-approved treatment specifically for SLE. Benlysta works by blocking the activity of B-lymphocyte stimulator (BLyS), a protein that plays a role in the overactive immune response seen in SLE. It is administered as an intravenous infusion every four weeks. The Benlysta market is composed of a range of companies that produce and distribute the drug. These include pharmaceutical companies such as GlaxoSmithKline, Human Genome Sciences, and Merck, as well as biotechnology companies such as Humanigen and BioCryst Pharmaceuticals. Additionally, there are a number of generic drug manufacturers that produce generic versions of Benlysta. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
